Neuren Pharmaceuticals Limited (ASX: NEU)

Market Cap	1.64B
Revenue (ttm)	193.34M
Net Income (ttm)	117.29M
Shares Out	127.01M
EPS (ttm)	0.89
PE Ratio	14.43
Forward PE	18.19
Dividend	n/a
Ex-Dividend Date	n/a

Volume	332,590
Average Volume	512,072
Open	13.00
Previous Close	12.90
Day's Range	12.96 - 13.70
52-Week Range	10.90 - 24.25
Beta	2.20
RSI	59.88
Earnings Date	Feb 28, 2025

About Neuren Pharmaceuticals

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide), which has been registered to treat Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid, and in Phase 2 clinical trial for the treatment of Angelman, Pitt Hopkins, and Prader...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Employees: 8
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: NEU

Financial Performance

In 2023, Neuren Pharmaceuticals's revenue was 231.94 million, an increase of 1404.46% compared to the previous year's 15.42 million. Earnings were 157.08 million, an increase of 85270.11%.